Janssen Pharmaceutical – Milvexian Receives US FDA Fast Track Approval for All Three Indications Being Evaluated in Phase 3 Librexia Program, Ischemic Stroke, Acute Coronary Syndrome, and Atrial Fibrillation – Marketscreener.com

Janssen Pharmaceutical – Milvexian Receives US FDA Quick Monitor Approval for All Three Indications Below Analysis in Section 3 Librexia Program, Ischemic Stroke, Acute Coronary Syndrome, and Atrial Fibrillation marketscreener.com
#Janssen #Pharmaceutical #Milvexian #Receives #FDA #Quick #Monitor #Approval #Indications #Evaluated #Section #Librexia #Program #Ischemic #Stroke #Acute #Coronary #Syndrome #Atrial #Fibrillation #Marketscreenercom